What development phase is Fundyl in?

Fundyl is FDA-approved (marketed).

What is the generic name of Fundyl?

ENPROSTIL is the generic (nonproprietary) name of Fundyl.

Last reviewed 2026-04-20 · How we verify

Fundyl (ENPROSTIL)

FDA-approved active Small molecule Quality 10/100

Enprostil (Fundyl) is a marketed prostaglandin E2 receptor EP3 subtype agonist used primarily to reduce inflammation and stomach acid production. Its key strength lies in its unique mechanism of action, which differentiates it from off-patent competitors like misoprostol, which has four generics available. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition and potential revenue erosion.

At a glance

Generic name	ENPROSTIL
Drug class	enprostil
Target	Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fundyl CI brief — competitive landscape report
Fundyl updates RSS · CI watch RSS